Merck and Daiichi Sankyo Expand their Partnership to Include Development of MK-6070
Shots:
- Under the expanded partnership, both will jointly develop & commercialize Merck’s MK-6070 globally, excl. Japan, where Merck will exclusively handle its manufacturing & supply
- Merck will obtain $170M upfront & has satisfied contingent obligation from the original agreement. Both of them will share R&D and commercialization costs plus profits globally (excl. Japan) with Daiichi Sankyo getting sales-based royalty. R&D costs for MK-6070 + ifinatamab deruxtecan (I-DXd) will be shared as per the original agreement. Merck will record global MK-6070 sales
- MK-6070 (T-cell engager targeting DLL3) is currently under P-I/II study. The companies anticipate to assess MK-6070 with I-DXd for SCLC & in other potential combinations
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
